[前列腺癌的内分泌治疗]
[Endocrine therapy of prostatic cancer].
作者信息
Shimazaki J, Fuse H, Zama S
出版信息
Gan No Rinsho. 1985 Jul;31(9 Suppl):1195-201.
PMID:4057576
Abstract
Response rate of prostatic cancer to endocrine therapy is approximately 80%, but more than half of responders show relapse by five years. Factors influencing prognosis are histological grade, stage, effect of elevated acid phosphatase, and androphilic protein observed histochemically. Relapse may be attributable to progression and clonal selection.
摘要
前列腺癌对内分泌治疗的缓解率约为80%，但超过半数的缓解者在五年内会出现复发。影响预后的因素有组织学分级、分期、酸性磷酸酶升高的影响以及组织化学观察到的亲雄激素蛋白。复发可能归因于疾病进展和克隆选择。
相似文献
1
[Endocrine therapy of prostatic cancer].[前列腺癌的内分泌治疗]
Gan No Rinsho. 1985 Jul;31(9 Suppl):1195-201.
2
[Treatment of prostatic cancer].[前列腺癌的治疗]
Gan To Kagaku Ryoho. 1988 Feb;15(2):212-8.
3
4
[Prostatic carcinoma. I: Androgen dependency of prostatic carcinoma].[前列腺癌。I：前列腺癌的雄激素依赖性]
Gan To Kagaku Ryoho. 1988 Apr;15(4 Pt 2-1):909-16.
5
6
[Progress of endocrine therapy for prostate cancer and results].[前列腺癌内分泌治疗的进展与结果]
Gan To Kagaku Ryoho. 1996 Mar;23(4):413-7.
7
Prostatic cancer: endocrine treatment.前列腺癌：内分泌治疗
Turk J Pediatr. 1984;26(1-4):273-6.
8
Endocrine treatment of prostate cancer.前列腺癌的内分泌治疗
J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. doi: 10.1016/j.jsbmb.2004.10.005. Epub 2004 Dec 31.
9
10
[Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].[内分泌治疗一年后再次活检与局限性前列腺癌长期预后的相关性]
Gan To Kagaku Ryoho. 2005 Jan;32(1):57-63.
Zotero 插件